174688-78-9
Chemical Structure
CH 275
- CAS No.: 174688-78-9
- Formula:C74H96N14O15S2
- Molecular Weight:1485.77
IUPAC Name: (4R,7S,10S,13S,16S,19S,22R,25S,28S,31S,34R)-22-((1H-indol-3-yl)methyl)-34-amino-31-(4-aminobutyl)-13,25,28-tribenzyl-10,16-bis((R)-1-hydroxyethyl)-7-(hydroxymethyl)-19-(4-((isopropylamino)methyl)benzyl)-6,9,12,15,18,21,24,27,30,33-decaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decaazacyclopentatriacontane-4-carboxylic acid
InChIKey: SYHQUPOPQRNSKD-SKMHOITNSA-N
SMILES: O=C(N[C@H](C(N[C@@](C(N[C@H](C(N[C@@](C(N[C@H](C(N1)=O)CO)=O)([H])[C@H](O)C)=O)CC2=CC=CC=C2)=O)([H])[C@H](O)C)=O)CC(C=C3)=CC=C3CNC(C)C)[C@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@H](CSSC[C@H]1C(O)=O)N)=O)CCCCN)=O)CC4=CC=CC=C4)=O)CC5=CC=CC=C5)=O)CC6=CNC7=CC=CC=C67
Biological Activity: CH 275 is a peptidic somatostatin analog that acts as an agonist of SST1 (IC50 = 30.9 nM, Ki = 52 nM). The IC50 values of CH 275 for sst3, sst4, sst2, and sst5 are 345 nM, >1 μM, >10 μM, and >10 μM, respectively. CH 275 binds to SSTR1 via the IAmp9-Asp137 ion pair interaction and the hydrophobic interaction between the isopropyl group of IAmp9 and Leu107, and reduces the extracellular acidification rate. CH 275 induces weak sst1 internalization, exerts immunosuppressive effects on macrophages, and decreases macrophage viability, MCP-1 expression/secretion, and IL-8 secretion, but does not alter proMMP-9 secretion or IL-8 mRNA levels. CH 275 reduces hippocampal β-amyloid levels and alleviates plaque pathology without inducing hippocampal microglial activation. CH 275 is used in research on Alzheimer's disease, Parkinson's disease, and depression[1][2][3][4][5].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
CH 275 | 99.52% | CH 275 is a peptidic somatostatin analog that acts as an agonist of SST1 (IC50 = 30.9 nM, Ki = 52 nM). The IC50 values of CH 275 for sst3, sst4, sst2, and sst5 are 345 nM, >1 μM, >10 μM, and >10 μM, respectively. CH 275 binds to SSTR1 via the IAmp9-Asp137 ion pair interaction and the hydrophobic interaction between the isopropyl group of IAmp9 and Leu107, and reduces the extracellular acidification rate. CH 275 induces weak sst1 internalization, exerts immunosuppressive effects on macrophages, and decreases macrophage viability, MCP-1 expression/secretion, and IL-8 secretion, but does not alter proMMP-9 secretion or IL-8 mRNA levels. CH 275 reduces hippocampal β-amyloid levels and alleviates plaque pathology without inducing hippocampal microglial activation. CH 275 is used in research on Alzheimer's disease, Parkinson's disease, and depression. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Armani C, et al. Expression, pharmacology, and functional role of somatostatin receptor subtypes 1 and 2 in human macrophages. Journal of leukocyte biology. 2007 Mar;81(3):845-55.
- [2]. Chen L, et al. Structural basis for the binding specificity of a SSTR1-selective analog of somatostatin. Biochemical and biophysical research communications. 1999 May 19;258(3):689-94. [Content Brief]
- [3]. Vasilaki A, et al. The somatostatin receptor (sst1) modulates the release of somatostatin in the nucleus accumbens of the rat. Neuropharmacology. 2004 Sep;47(4):612-8.
- [4]. Nilsson P, et al. Somatostatin receptor subtypes 1 and 4 regulate neprilysin, the major amyloid-β degrading enzyme in brain. Journal of Alzheimer's disease : JAD. 2026 Jan;109(2):651-666.
- [5]. Rivier JE, et al. Potent somatostatin undecapeptide agonists selective for somatostatin receptor 1 (sst1). J Med Chem. 2001 Jun 21;44(13):2238-46. [Content Brief]
